Mice in the 11-mix community had a greater response to anti-PD−1 therapy, an immune checkpoint inhibitor (ICI) used in cancer treatment, and had an increased frequency of IFNγ+ CD8+ tumor-infiltrating lymphocytes (TILs). This evidence concerns the gene PDCD1 and cancer.